03
Jun 2015With a crucial CAR-T trial looming for Cellectis, a confident André Choulika is laying it all on the line
André Choulika does not mince words. The Cellectis CEO is an outspoken champion of all things related to the company he founded 15 years ago.
03
Jun 2015Alzheimer’s biotech eyes $300M in a scaled-up IPO
Axovant Sciences, heading toward Phase III with an ex-GlaxoSmithKline treatment for Alzheimer’s disease, has upped its IPO hopes to more than $300 million, betting it can win FDA approval where many others have failed.
03
Jun 2015Active Biotech focuses the operations on the laquinimod project and adjusts the organization
LUND, Sweden, June 1, 2015 — Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the company has made a notification of planned redundancies of 47 of its employees, which means a…
03
Jun 2015L’Oreal Partners With Innovative Biotech Firm
“The collaboration will draw on L’Oreal’s experience in beauty product development and Organovo’s proprietary NovoGen Bioprinting Platform to grow bioprinted skin for product testing.”
02
Jun 2015Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival
Puma Biotechnology, Inc. , a development stage biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma’s investigational drug PB272 for the extended adjuvant treatment of breast cancer .
02
Jun 2015UP govt to promote biotechnology industry – The Times of India
State government will promote biotechnology industry in UP.
01
Jun 2015Rare-disease biotech companies surge in value – but some see a bubble
Orphan drug designation comes with many perks, including sky-high prices and protection from generic competition
01
Jun 2015Préouverture Paris : les biotechs s’agitent encore
Les marchés financiers continuent toujours et encore de vivre au gré des nouvelles en provenance de Grèce…
01
Jun 2015La biotech française Cellectis pourrait être rachetée par l’américain Pfizer
Pfizer, numéro un mondial de la pharmacie qui détient déjà 9,47% de Cellectis, a contacté la société en vue d’une fusion, avec une proposition pour un montant de 1,5 milliard d’euros, d’après le Financial Times.
29
May 2015California Stem Cell Report: $15 Million for Calimmune and California Stem Cell HIV Trial
Source: californiastemcellreport.blogspot.fr